Literature DB >> 14612935

XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways.

Edith Mensah-Osman1, Ayad Al-Katib, Mahmoud Dandashi, Ramzi Mohammad.   

Abstract

We have previously reported that XK469 inhibited topoisomerase (topo) IIbeta, in Waldenstrom's macroglobulinemia cell line (WSU-WM) however the inhibition alone is not sufficient to induce apoptosis. In this study, the apoptotic potential of XK469 and its mechanism in WSU-WM cell line was investigated. Exposure of WSU-WM cells to XK469 caused a decrease in viable cell number in a dose-dependent manner. In addition, XK469 caused the activation of caspase 3 resulting in subsequent cleavage of PARP. These events were preceded by the release of cytochrome c from the mitochondria to the cytosol. Simultaneous exposure of cells to cyclosporin A prevented the release of cytochrome c to cytosol and reduced the loss of viability. XK469 caused the activation of p53 with up-regulation of p53-dependent proteins such as Bax, p21, Gadd 45 and cyclin B1 in association with G2M arrest. The addition of ubiquitin carboxyl terminal hydrolase (UCH-L1) inhibitor (NaBH4) inhibited up-regulation of p53 and p53 related molecules by XK469 and reduced the loss of viability. Pre-incubation with NOK-1, a monoclonal antibody that prevents Fas-Fas ligand interaction and is inhibitory to Fas signaling interfered with XK469 induced activation of caspase 8 and also reduced the loss of viability. Simultaneous exposure of all three inhibitors (cyclosporin A, NaBH4 and NOK-1) abrogated the toxicity of XK469 by 95%. These data define multiple sequences of biochemical events that mediate cell death induced by XK469. Our study suggests a complex mechanistic cascade of XK469-mediated apoptosis that involves Fas signaling pathway, ubiquitination, p53 activation and cytochrome c release.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612935

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth.

Authors:  Nisha C Kakodkar; Radhika Peddinti; Morris Kletzel; Yufeng Tian; Lisa J Guerrero; Samir D Undevia; David Geary; Alexandre Chlenski; Qiwei Yang; Helen R Salwen; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

2.  The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents, XK469 and SH80.

Authors:  David Kessel; John J Reiners; Stuart T Hazeldine; Lisa Polin; Jerome P Horwitz
Journal:  Mol Cancer Ther       Date:  2007-01       Impact factor: 6.261

3.  The chemotherapeutic agents XK469 (2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid) and SH80 (2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy}propionic acid) inhibit cytokinesis and promote polyploidy and induce senescence.

Authors:  John J Reiners; Miriam Kleinman; Aby Joiakim; Patricia A Mathieu
Journal:  J Pharmacol Exp Ther       Date:  2008-12-09       Impact factor: 4.030

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.